OsimertinibAcquired resistance in EGFR-mutated lung cancer: case report

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2021年 / 1836卷 / 1期
关键词：
D O I：
10.1007/s40278-021-88438-7
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：619 / 619
相关论文
共 50 条
  • [21] EGFR-mutated lung adenocarcinoma with choroidal oligometastasis during treatment with gefitinib: a case report
    Hashimoto, Takafumi
    Osoegawa, Atsushi
    Abe, Miyuki
    Oki, Ryoko
    Karashima, Takashi
    Takumi, Yohei
    Kamada, Kosuke
    Miyawaki, Michiyo
    Sugio, Kenji
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2024, 13 (03) : 204 - 208
  • [22] Breast metastasis from EGFR-mutated lung adenocarcinoma: A case report and review of the literature
    Ota, Takayo
    Hasegawa, Yoshikazu
    Okimura, Akira
    Sakashita, Katsuya
    Sunami, Takeshi
    Yukimoto, Kiyotaka
    Sawada, Ryugo
    Sakamoto, Kazutsugu
    Fukuoka, Masahiro
    CLINICAL CASE REPORTS, 2018, 6 (08): : 1510 - 1516
  • [23] CHRONIC NICOTINE EXPOSURE MEDIATES RESISTANCE TO EGFR-TKI IN EGFR-MUTATED LUNG CANCER VIA EGFR SIGNAL
    Hayashi, Hidetoshi
    Togashi, Yosuke
    Okamoto, Kunio
    Fumita, Soichi
    Terashima, Masato
    Sakai, Kazuko
    Fujita, Yoshihiko
    Tomida, Shuta
    Nakagawa, Kazuhiko
    Nishio, Kazuto
    ANNALS OF ONCOLOGY, 2014, 25
  • [24] Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal
    Togashi, Yosuke
    Hayashi, Hidetoshi
    Okamoto, Kunio
    Fumita, Soichi
    Terashima, Masato
    de Velasco, Marco A.
    Sakai, Kazuko
    Fujita, Yoshihiko
    Tomida, Shuta
    Nakagawa, Kazuhiko
    Nishio, Kazuto
    LUNG CANCER, 2015, 88 (01) : 16 - 23
  • [25] Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report
    Matsuura, Hiroaki
    Higo, Hisao
    Kuribayashi, Tadahiro
    Tamaoki, Akihiko
    Nakasuka, Takamasa
    Uno, Mari
    Makimoto, Go
    Ninomiya, Kiichiro
    Fujii, Masanori
    Rai, Kammei
    Ichihara, Eiki
    Hotta, Katsuyuki
    Miyahara, Nobuaki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    Ohashi, Kadoaki
    THORACIC CANCER, 2024, 15 (17) : 1390 - 1394
  • [26] Factors affecting outcome in resected EGFR-mutated lung cancer
    Eide, Inger Johanne Zwicky
    Nilssen, Yngvar
    Lund-Iversen, Marius
    Brustugun, Odd Terje
    ACTA ONCOLOGICA, 2022, 61 (06) : 749 - 756
  • [27] Novel LZTR1 germline mutation as a mechanism of resistance to osimertinib in EGFR-mutated lung adenocarcinoma: a case report
    Park, Wai
    Fricke, Jeremy
    Mambetsariev, Isa
    Velasquez, Giovanny
    Nadaf-Rahrov, Reza
    Dingal, Shaira Therese
    Kim, Pauline
    Babikian, Razmig
    Amini, Arya
    Afkhami, Michelle
    Salgia, Ravi
    TRANSLATIONAL LUNG CANCER RESEARCH, 2025, 14 (02) : 625 - 630
  • [28] EGFR-mutated lung cancer in Li-Fraumeni syndrome
    Michalarea, Vasiliki
    Calcasola, Matthew
    Cane, Paul
    Tobal, Khalid
    Izatt, Louise
    Spicer, James
    LUNG CANCER, 2014, 85 (03) : 485 - 487
  • [29] Gefitinib/osimertinibAcquired resistance in lung adenocarcinoma: case report
    Reactions Weekly, 2018, 1713 (1) : 177 - 177
  • [30] Adjuvant therapy with Osimertinib in resectable EGFR-mutated lung cancer
    Gassa, Asmae
    Ozkan, Filiz
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2021, 27 (02): : 172 - 173
12345